T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML

Background Immunotherapy development in pediatric AML is lagging because of dearth of validated AML-specific targets. We showed recently that mesothelin (MSLN) is highly expressed on the leukemia cell surface in a subset of pediatric AML patients, and validated MSLN as a therapeutic target using ant...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.1280-1280
Hauptverfasser:	Gopalakrishnapillai, Anilkumar, Correnti, Colin, Pilat, Kristina, Lin, Ida, Chan, Albe Man Kid, Bandaranayake, Ashok D., Mehlin, Christopher, Kisielewski, Anne, Hamill, Darcy, Kaeding, Allison, Meshinchi, Soheil, Olson, James, Kolb, E. Anders, Barwe, Sonali P.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!